ScreenerHero

IRD Opus Genetics, Inc.

NAS · US · Healthcare · Biotechnology · opusgtx.com
4.410USD+0.68%Mkt Cap: 366.89M $P/E: —

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additio…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap366.89M USD
Enterprise Value311.79M USD
Revenue (TTM)9.86M USD
Gross Profit-28.77M USD
Net Income (TTM)-49.59M USD
Revenue/Share0.12 USD
Last Price4.410 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees27
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.13
PEG—
EV/EBITDA-6.17
EV/Revenue31.63
P/S36.97
P/B-27.90
EPS (TTM)-1.27
EPS (Forward)-0.71
52W Range
1.50052% of range7.070
52W High7.070 USD
52W Low1.500 USD
Profitability
Gross Margin-291.85%
Oper. Margin-2182.78%
EBITDA Margin0.00%
Profit Margin-349.33%
ROE-323.11%
ROA-98.70%
Growth
Revenue Growth-73.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.25M USD
CapEx (TTM)—
FCF Margin-391.19%
FCF Yield-10.51%
Net Debt-52.61M USD
Net Debt/EBITDA1.04
Balance Sheet
Debt/Equity0.07
Current Ratio12.19
Quick Ratio11.87
Book Value/Sh-0.16 USD
Cash/Share1.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 6, 2020
Splits
Last Split1:4
Split DateNov 6, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)13.41 USD
Upside (mean)+204.1%
Target Range8.000 USD – 20.00 USD
8.000+204.1% to mean20.00
# Analysts17
Ownership
Shares Out.83.20M
Float64.68M
Insiders12.23%
Institutions69.27%
Short Interest
Short Ratio2.8d
Short % Float15.90%
Short % Out.15.12%
Shares Short12.58M
Short (prev mo.)11.25M
Technical
SMA 504.384 (+0.6%)
SMA 2004.010 (+10.0%)
Beta0.62
S&P 52W Chg16.45%
Avg Vol (30d)4.00M
Avg Vol (10d)2.00M
Technical Indicators
RSI (14)44.7
MACD0.0141
MACD Signal0.1487
MACD Hist.-0.1345
BB Upper6.163 USD
BB Middle5.034 USD
BB Lower3.905 USD
BB Width44.85%
ATR (14)0.4215 USD
Vol Ratio (20d)0.36x